Go Back   Drugs.com > Announcements > Latest Drug Related News
Forgotten Password?
Register FAQ Calendar Search Today's Posts Mark Forums Read

Latest Drug Related News Drugs.com's web-based discussion board for questions and comments on latest drug related news, FDA approvals and clinical trials.

Reply
 
Thread Tools Display Modes
  #1  
Old 02-21-2006, 03:20 PM
Member
 
Join Date: Oct 2004
Location: USA.
Posts: 350
Default Strattera and Suicide

Strattera - 130 Reports Of Suicidality In One Month
February 15, 2006. By Evelyn Pringle
From: http://www.lawyersandsettlements.com...strattera.html

A not yet released discussion paper written by the British Medicines and Healthcare Regulatory Agency, reveals that last fall, there were 130 reports of suicidality in a single month by patients treated with the attention deficit drug Strattera.

In addition, the paper reveals that there have also been more than 760 spontaneous reports of cardiac disorders, 172 reports of liver damage, and about 20 reports of completed suicides.

The large number of adverse event reports are exposed in a December 9, 2005, paper sent to the Swedish Medical Products Agency by the British agency. The information was obtained through FOIA-requests, and was released under a court order, according to Swedish investigative reporter Janne Larsson.

A press release on the British discussion paper will be issued tomorrow morning, on February 16, 2006.

Drug making giant, Eli Lilly originally sought FDA approval of Strattera as an antidepressant and was unsuccessful. The drug has since been marketed as a treatment for ADHD. Strattera is approved for use with children and adult patients. However, the drug has not been tested in children less than 6 years of age or in geriatric patients, according Lilly.

Strattera is selective norepinephrine reuptake inhibitor, and the first non-stimulant drug approved to treat ADHD. Since Strattera is chemically similar to depression drugs linked to suicidal thoughts in children in 2004, last year the FDA ordered Lilly to analyze its data on Strattera.

The 12 short-term (6-18 weeks) trials reviewed involved more than 2200 patients, including 1357 receiving Strattera and 851 receiving placebo. The analysis found a greater risk of suicidal thinking during the first few months in those receiving Strattera. The average risk of suicidal thinking was about 4 per thousand with Strattera compared to no events in placebo-patients. There was 1 suicide attempt in a patient treated with Strattera.
Reply With Quote
  #2  
Old 02-21-2006, 04:31 PM
bn7 bn7 is offline
Member
 
Join Date: Oct 2005
Location: .
Posts: 87
Default

Feds Recommend Warnings on ADHD Drugs.
http://abcnews.go.com/Health/wireSto...C-RSSFeeds0312
Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is Off
HTML code is Off
Trackbacks are On
Pingbacks are On
Refbacks are Off



All times are GMT -5. The time now is 02:14 AM.


Powered by vBulletin®
Copyright ©2000 - 2009, Jelsoft Enterprises Ltd.
SEO by vBSEO ©2009, Crawlability, Inc.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18